



TELEPHONE: 512/536-4591  
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:  
GSHISHIMA@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:  
512/536-3081

14C 09845 612  
6w 03,0  
FULBRIGHT & JAWORSKI L.L.P.  
A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

1300 SEE  
04/26  
9/8/02  
HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

BEST AVAILABLE COPY

March 26, 2002

FILE: UTSD:795US  
10101381

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

March 26, 2002

Date

Steven L. Highlander

BOX MISSING PARTS  
Commissioner for Patents  
Washington, DC 20231

RE: *U.S. Patent Application No. 09/845,612 Entitled: A CLASS OF 12 MER PEPTIDES THAT INHIBIT THE FUNCTION OF THE MITOTIC CHECK POINT PROTEIN MAD2 - by Hongtao Yu et al.*  
(Client Reference No. UTSD:795US)

Commissioner:

Enclosed for filing in the above-referenced patent application is:


- (1) Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- (2) Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Dated February 8, 2002;
- (3) Statement as Required Under 37 C.F.R. § 1.821(f); Paper Copy of Sequence Listing; Computer Readable Form (CRF); and
- (4) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Commissioner for Patents  
March 26, 2002  
Page 2

**BEST AVAILABLE COPY**

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10101381/SLH.

Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,642

SLH/cpj  
Encl.: As stated

**BEST AVAILABLE COPY**

APR 10 2002



## UNITED STATES PATENT AND TRADEMARK OFFICE

&amp; TRADEMARKS

 COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D C 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/845,612	04/30/2001	Hongtao Yu	UTSD:0795

Steven L. Highlander  
 Fulbright & Jaworski L.L.P.  
 Suite 2400  
 600 Congress Avenue  
 Austin, TX 78701

RECEIVED  
 Date(s) Docketed: 04/18/02 Seq  
 Listing file 04/18/02  
 (final decision)  
 FEB 15 2002  
 Client: UTSD: 795  
 Attorney(s): DPTSH  
 Initials: JCPZ

 CONFIRMATION NO. 2625  
**FORMALITIES LETTER**  
  
 OC000000007451156\*

Date Mailed: 02/08/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice MUST be returned with the reply.*

Customer Service Center  
 Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



#11

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C., 20231, on the date below:	
March 26, 2002 Date	Steven L. Highlander

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
**HONGTAO YU ET AL.**

Serial No.: 09/845,612

Filed: APRIL 30, 2001

For: A CLASS OF 12MER PEPTIDES THAT  
INHIBIT THE FUNCTION OF THE  
MITOTIC CHECK POINT PROTEIN  
MAD2

Group Art Unit: 1646

Examiner: UNKNOWN

Atty. Dkt. No.: UTSD:795US/SLH

**STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(f)**


**BOX SEQUENCE**

Commissioner for Patents  
Washington, D.C. 20231

Commissioner:

Submitted herewith is a computer readable form and a paper copy of the sequence listing of those sequences in the captioned patent application. The computer readable form of the sequence listing is the same as the paper copy of the sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed computer readable and paper forms of the sequence listing.

Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 536-3184

Date: March 26, 2002